Statistics

Total Visits

Views
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study31

Select a period of time:

Number of views in the range

Views
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study19

Views

Views
October 20240
November 20241
December 20240
January 20250
February 20253
March 202515
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States4
 

Top cities views

Views
Seattle1